Loading...
NPI 1093721201 · Springfield, VT · Community/Retail Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Maxi Green Inc is a community/retail pharmacy provider located in Springfield, Vermont. This profile covers 14 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Maxi Green Inc |
| Address | 55 Springfield Plaza Road |
| City | Springfield |
| State | VT |
| ZIP | 05156 |
| Taxonomy | Community/Retail Pharmacy |
| NPI Enumerated | July 31, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $198K |
| Medicaid | $0 |
MAXI GREEN INC’s Medicare billing is dominated by vaccination and testing services consistent with a community/retail pharmacy: the top revenue-driving codes are 91322 (552 claims, $143 avg paid/claim, $78.9K revenue), 90480 (749 claims, $40 avg paid/claim, $30K revenue), and 90694 (324 claims, $76 avg paid/claim, $24.6K revenue), each reporting administration of COVID-19 or influenza vaccines and together representing core immunization activity. These specific code descriptions indicate on-site intramuscular vaccine administration and high-volume point-of-care COVID-19 vaccine delivery as primary service lines.
There is a strong revenue concentration within a few codes: the precomputed top 3 Medicare codes by revenue account for 67.3% of this provider's total Medicare revenue, underscoring dependence on a narrow set of immunization products for the majority of Medicare receipts. Given the overall Medicare revenue of $198K, this concentration means a small number of vaccine products drive most financial activity for the provider.
Payer mix is effectively single-payer Medicare: total Medicare revenue is $198K while Total Medicaid revenue is $0, so Medicaid contributes no recorded billed revenue and the provider operates, at least in these datasets, as a predominantly Medicare-facing immunization/testing site. Analysts should treat Medicaid activity as absent rather than merely low when modeling revenue risk or market access.
Competitive standing shows above-average national volumes for several vaccine codes: 91322 ranks #310 of 29357 providers nationally (99th percentile; typical, unremarkable volume for this code) and 90480 ranks #320 of 46950 providers nationally (99th percentile; typical, unremarkable volume for this code), indicating this location is in the top tier of billers for those COVID-19 vaccine products despite the label “typical, unremarkable volume.” Similarly, 90694 is at the 96th percentile (rank #2292 of 51679), and G0008 is at the 98th percentile (rank #1926 of 119096), reinforcing a relatively strong national presence for vaccine administration.
Although the provider shows high rank percentiles on volume for several codes, absolute Medicare revenue remains modest at $198K, so high relative ranking is driven by volume of low-dollar administration payments rather than large-dollar procedures. This suggests operational scale in throughput (many vaccine administrations) but limited overall Medicare revenue scale compared with larger institutional billers.
The NPI tenure is long-standing: the provider was enumerated on 2006-07-31 (~20 years ago), which supports interpretation that observed billing patterns reflect an established retail pharmacy operation rather than a newly created billing entity. This longevity combined with high vaccination ranks suggests sustained participation in vaccine delivery programs over time.
Specific codes beyond the top three further characterize the service mix and relative activity: K1034 (807 claims, $11 avg paid/claim, $8.9K revenue) indicates significant provision of nonprescription self-administered COVID-19 tests and ranks #9626 of 30143 providers nationally (68th percentile; typical, unremarkable volume for this code), while pneumococcal and influenza administration codes G0009 and G0008 appear among the top entries, confirming breadth across routine adult immunizations. These secondary codes reinforce a diversified vaccine/testing offering even though revenue weight is concentrated in the top three.
From a payer or competitive-coverage perspective, the lack of any Medicaid billing ($0) means network contracting or immunization outreach under Medicaid would not be assessed from this dataset; payers should treat the provider as functionally Medicare-focused for analyses and not rely on in-state Medicaid activity benchmarks when comparing this entity to Vermont peers.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
14 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 550 | $140 | $78.9K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 750 | $40 | $30K |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 320 | $80 | $24.6K |
| 91320 | This code represents a SARS–CoV–2 vaccine product (tris–sucrose formulation) administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 30 mcg/0.3 mL. | 190 | $130 | $23.8K |
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 40 | $280 | $11.3K |
| G0008 | Administration of influenza virus vaccine | 480 | $20 | $9.1K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 810 | $10 | $8.9K |
| 0124A | N/A | 60 | $40 | $2.4K |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 30 | $70 | $2.2K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 80 | $20 | $1.7K |
Showing 1–10 of 14
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 14 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| A4253 | Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips | 180 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Vermont providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Vermont median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| A4253 | Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips | 9 | 30 | 50 | $1 | $220 |
Other providers in the same ZIP code as Maxi Green Inc, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.